COMPASS Pathways (CMPS) Stock Forecast & Price Target

Compass Pathways is attractive because its COMP360 program has moved from data generation into an FDA-reviewed rolling NDA, with 26-week Phase 3 durability and a clean safety profile that strengthen the case for approval in treatment-resistant depression. The company is also building a credible commercial launch path, with more than 8,000 interventional psychiatry clinics in its potential footprint, sales-force recruiting underway, eight collaboration partners covering more than 1,000 sites, and about $433.3 million of cash supporting runway into 2028. Additional upside comes from a favorable regulatory setup and pipeline optionality, including expected DEA rescheduling, a commercially favorable label, and ongoing PTSD and VA-funded studies that could expand COMP360 beyond TRD.

Compass Pathways is viewed negatively because its investment case depends heavily on COMP-360 and other pipeline programs succeeding in clinical trials, despite meaningful risks of failure, safety setbacks, and potential inability to secure FDA approval. The company also faces substantial regulatory and commercial uncertainty, including competition, insurer pressure, and other market forces that could limit adoption even if development progresses. In addition, the risk of a dilutive equity offering is especially concerning for a biotech with no diversified operating base and only one operating segment, since financing needs tied to ongoing development could further weigh on shareholder returns.